Brentuximab vedotin drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Brentuximab vedotin drug can be ordered at the same time. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Adcetris® |
| INN | Brentuximab Vedotin |
| API type | Brentuximab Vedotin is an antibody-drug conjugate composed of a CD30-directed monoclonal antibody (recombinant chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule agent monomethyl auristatin E (MMAE) |
| Pharmacotherapeutic group | Antineoplastic agents |
| ATC code | L01XC12 |
| Target of antibody | CD-30 |
| General function | The monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells. The cytotoxic molecule then enters the cancer cells and stops them from dividing, and the cancer cells eventually die. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Brentuximab vedotin is an ADC that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | The primary objective was to evaluate the effect of brentuximab vedotin on cardiac ventricular re-polarization and the predefined primary analysis was the change in QTc from baseline to multiple time points in Cycle 1. The upper 90% confidence interval (CI) around the mean effect on QTc was < 10 msec at each of the Cycle 1 and Cycle 3 post-baseline time points. These data indicate the absence of clinically relevant QT prolongation due to brentuximab vedotin administered at a dose of 1.8 mg/kg every 3 weeks in patients with CD30-expressing malignancies. |
| Original license holder | Takeda Pharma A/S |
| Marketing authorisation numbers | EU/1/03/256/022 |
| Marketing authorisation holder | Takeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand Denmark |
| Name of the manufacturer of the biological active substance | Takeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand Denmark |
| Name and address of the manufacturer(s) responsible for batch release | Takeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand Denmark |
| Max shelf life | 48 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Citric acid monohydrate Sodium citrate dihydrate α,α-Trehalose dihydrate Polysorbate 80 |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
